false
0000727346
0000727346
2026-05-14
2026-05-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 14, 2026
SELECTIS
HEALTH, INC.
(Exact
Name of Registrant as Specified in its Charter)
| Utah
|
|
0-15415
|
|
87-0340206
|
(State
or other jurisdiction
of
incorporation) |
|
Commission
File Number |
|
(I.R.S.
Employer
Identification
number) |
600
17th Street, Suite 2800
South, Denver, CO.
80202
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (720) 680-0808
(Former
name or former address, if changed since last report)
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| ITEM
5.02 |
DEPARTURE
OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS |
Effective
May 14, 2026 the Board of Directors of Selectis Health, Inc., a Utah corporation (the “Company”) and Adam Desmond (“Desmond”)
agreed that he would resign all positions with the Company including CEO, CFO of the Company and a member of the Board of Directors.
A Separation Agreement and Release has been drafted and signed and is filed herewith as Exhibit 10.1.
On
May 15, 2026, the Board of Directors of the Company appointed Krystal Eckhart to serve as the Company’s Interim CEO and CFO. Ms.
Eckhart currently serves as a Vice President of the Company. Below is the biographical information for Ms. Eckhart.
Krystal
Eckhart, age 41, is an accomplished healthcare revenue cycle and financial operations leader with 15+ years of progressive management
experience across skilled nursing facilities and multi-state healthcare organizations. Ms. Eckhart has worked with the Company in various
capacities since 2016. Currently she serves as a Vice President of Revenue Management, specializing in Lead Medicare and Medicaid operations
for 9 multi-state healthcare facilities; overseeing SEC audits, financial reporting, AR/AP operations, and acquisition-related financial
processes. She also manages corporate and facility-level employees through training, performance oversight, and operational support.
Prior to holding this position Ms. Eckhart served as the Director of Accounts Receivable for the Company focusing on directing Medicare,
Managed Care, and Medicaid billing operations in Oklahoma and Georgia; supervising business office managers and maintaining oversight
of resident trust accounts; managing audits, aging reviews, month-end close processes, and corporate reporting functions.
| Item
9.01 |
Financial
Statements and Exhibits |
| Exhibit
No. |
|
Description |
| 10.1 |
|
Separation Agreement and Release |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
| |
Selectis Health, Inc.
(Registrant)
|
| |
|
|
| Dated:
May 20, 2026 |
|
/s/
Clifford L. Neuman |
| |
|
Clifford
L. Neuman, Director |
